Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer

Gianluca Giannarini; Neeraj Agarwal; Andrea B Apolo; Alberto Briganti; Petros Grivas; Shilpa Gupta; Ashish M Kamat; Francesco Montorsi; Morgan Rouprêt; Andrea Necchi

doi:10.1016/j.euo.2021.05.008

Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer

Eur Urol Oncol. 2022 Jun;5(3):268-272. doi: 10.1016/j.euo.2021.05.008. Epub 2021 Jun 17.

Authors

Affiliations

¹ Urology Unit, Santa Maria della Misericordia University Hospital, Udine, Italy. Electronic address: gianluca.giannarini@hotmail.it.
² Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
³ Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
⁴ Urology Unit, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁵ Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
⁶ Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
⁷ Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ GRC 5 Predictive Onco-Uro, Sorbonne University, Urology, Pitié-Salpêtrière Hospital AP-HP, Paris, France.
⁹ Urology Unit, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy.

PMID: 34147473
DOI: 10.1016/j.euo.2021.05.008

Abstract

Novel immune checkpoint inhibitors hold promise for non-muscle-invasive bladder cancer. Cooperation between urologists and other multidisciplinary bladder cancer specialists can surmount the challenges involved in using these agents in bladder-sparing approaches. This strategy could deliver a new era of comprehensive evaluation and multimodal treatment for this patient population.

Publication types

Editorial

MeSH terms

Humans
Immune Checkpoint Inhibitors
Immunotherapy / methods
Urinary Bladder / diagnostic imaging
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / therapy
Urologists

Substances

Immune Checkpoint Inhibitors